Links to articles in the current and previous 2 issues of this bulletin are displayed below.
To receive email notifications about new issues of this bulletin, please email: richard.fallis@healthcarelibrary.qub.ac.uk
Arteriovenous access for hemodialysis: a review 10.1001/jama.2024.0535
BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms 10.1182/blood.2023022499
Biology of factor XI (review) 10.1182/blood.2023020719
Cell cross talk within the lymphoma tumor microenvironment: follicular lymphoma as a paradigm 10.1182/blood.2023021000
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy 10.1182/blood.2023022432
Degraders upgraded: the rise of PROTACs in hematological malignancies 10.1182/blood.2023022993
The essential microenvironmental role of oligomannoses specifically inserted into the antigen-binding sites of lymphoma cells 10.1182/blood.2023022703
Factor XI deficiency: phenotypic age-related considerations and clinical approach towards bleeding risk assessment 10.1182/blood.2023020721
The follicular lymphoma tumor microenvironment at single-cell and spatial resolution 10.1182/blood.2023020999
Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B-cell lymphoma 10.1182/blood.2023021002
Home versus in‐centre haemodialysis for people with kidney failure (updated Cochrane intervention review) 10.1002/14651858.CD009535.pub3
How I manage acute respiratory failure in patients with hematological malignancies 10.1182/blood.2023021414
How I reduce and treat posttransplant relapse of MDS 10.1182/blood.2023023005
Kurin Lock for blood culture collection (new NICE guideline MTG77)
Recent developments in the use of pyruvate kinase activators as a new approach for treating sickle cell disease 10.1182/blood.2023021167
T-cell dysfunctions in myelodysplastic syndromes 10.1182/blood.2023023166
Targeting factor XI and factor XIa to prevent thrombosis 10.1182/blood.2023020722
“Treatment with curative intent”: the emergence of genetic therapies for sickle cell anemia 10.1182/blood.2023021598
Blood (Mar-18th Apr); Cochrane Library (Mar-Apr); JAMA (18th Mar); NICE website (Apr)
Access to CAR T-cell therapy: Focus on diversity, equity and inclusion 10.1016/j.blre.2023.101136
CAR T-cell therapy in multiple myeloma: mission accomplished? 10.1182/blood.2023021221
Clinical decision support to enhance venous thromboembolism pharmacoprophylaxis prescribing for pediatric inpatients with COVID-19 10.1002/pbc.30843
The current challenges faced by people with hemophilia B 10.1111/ejh.14135
Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation 10.1097/BS9.0000000000000178
Haematopoietic stem cell health in sickle cell disease and its implications for stem cell therapies and secondary haematological disorders 10.1016/j.blre.2023.101137
Hoping for a normal life: Decision-making on hematopoietic stem cell transplantation by patients with a hemoglobinopathy and their caregivers 10.1002/pbc.30808
The lifelong natural history of clonal hematopoiesis and its links to myeloid neoplasia 10.1182/blood.2023019964
Myeloma and DNA damage 10.1182/blood.2023021384
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma 10.1182/blood.2023021348
The many facets of immune-mediated thrombocytopenia: Principles of immunobiology and immunotherapy 10.1016/j.blre.2023.101141
Measuring neurobehavioral side effects of corticosteroids in pediatric acute lymphoblastic leukemia: A scoping review 10.1002/pbc.30881
Neonatal hemophagocytic lymphohistiocytosis: A meta-analysis of 205 cases 10.1002/pbc.30894
Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (new Cochrane intervention review) 10.1002/14651858.CD014544.pub2
A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma 10.1016/j.blre.2023.101140
Red blood cell capacity of modern menstrual products: considerations for assessing heavy menstrual bleeding 10.1136/bmjsrh-2023-201895
Social determinants of health predict health outcomes following pediatric allogeneic hematopoietic stem cell transplant 10.1002/pbc.30892
Teclistamab-cqyv in multiple myeloma 10.1111/ejh.14121
Blood (Jan-Feb); Blood Reviews (Jan); Blood Science (Jan); BMJ Sexual and Reproductive Health (Jan); Cochrane Library (Feb-Mar); European Journal of Haematology (Mar); Pediatric Blood and Cancer (Mar-Apr)
Aiming for the cure in myeloma: Putting our best foot forward DOI: 10.1016/j.blre.2023.101116
Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta thalassaemia (new Cochrane intervention review) DOI: 10.1002/14651858.CD011626.pub3
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS) DOI: 10.1016/j.blre.2023.101128
Combining PTCy and ATG for GvHD prophylaxis in non-malignant diseases DOI: 10.1016/j.blre.2022.101016
The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment DOI: 10.1016/j.blre.2023.101117
Does PTCY increase the risk of infections? DOI: 10.1016/j.blre.2023.101092
Early and empirical high-dose cryoprecipitate for hemorrhage after traumatic injury: The CRYOSTAT-2 randomized clinical trial DOI: 10.1001/jama.2023.21019
Emergency department resuscitative endovascular balloon occlusion of the aorta in trauma patients with exsanguinating hemorrhage: The UK-REBOA randomized clinical trial DOI: 10.1001/jama.2023.20850
Hereditary transthyretin amyloidosis in the era of RNA interference, antisense oligonucleotide, and CRISPR-Cas9 treatments DOI: 10.1182/blood.2023019884
Hypertension in adults: diagnosis and management (updated NICE guideline NG136)
Innovations in RNA therapy for hemophilia DOI: 10.1182/blood.2022018661
The next horizon now that everyone has a donor: Precision allogeneic transplantation DOI: 10.1016/j.blre.2022.100990
Potential future direction of measurable residual disease evaluation in multiple myeloma DOI: 10.1182/blood.2023020284
Preservation of fertility in female patients with hematologic diseases DOI: 0.1016/j.blre.2023.101115
PTCy: The “new” standard for GVHD prophylaxis DOI: 10.1016/j.blre.2023.101096
Red blood cell transfusion: 2023 AABB international guidelines DOI: 10.1001/jama.2023.12914
Red blood cell transfusion in the intensive care unit DOI: 10.1001/jama.2023.20737
RNA interference therapy in acute hepatic porphyrias DOI: 10.1182/blood.2022018662
Small-volume blood collection tubes to reduce transfusions in intensive care: The STRATUS randomized clinical trial DOI: 10.1001/jama.2023.20820
Sources used: Blood (Nov); Blood Reviews (Nov); Cochrane Library (Nov, Dec); JAMA (21st Nov); NICE website (Nov)